Global /United States /Healthcare /Drug Manufacturers - General /SMNR

Semnur Pharmaceuticals, Inc.

SMNR

• OTCMKTS: SMNR • Delayed

5.00USD 0%

As of 13 June 2026, Semnur Pharmaceuticals, Inc. has a market cap of $1.15B USD, ranking #9919 globally and #2065 in the United States. It ranks #869 in the Healthcare sector, and #328 in the Drug Manufacturers - General industry.

Global Rank

9919

Country Rank

2065

Sector Rank

869

Industry Rank

328

Key Stats

Market Cap

$1.15BUSD

Enterprise Value

$1.17BUSD

Net Income (TTM)

-$160.42MUSD

PB Ratio

-55.5

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Henry Ji open_in_new

Employees

Founded

2013

Website

semnurpharma.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	-38%	-38%	-43%	-44%	-67%	-58%	-53%	-86%

News

Markets

Exchange	Ticker	Price	Quotes
OTC Markets (OTCMKTS / OTC) MIC: OTCM PRIMARY	SMNR ISIN: US81686G1058 Shares Out.: Shares Outstanding: 230.209M¹ Shares Float: 29.154M² TV: TradingView: OTC: SMNR SA: Stock Analysis: OTC: SMNR YF: Yahoo Finance: SMNR GF: Google Finance: OTCMKTS: SMNR BA: Barron's: SMNR MS: Morningstar: PINX: SMNR	5.00 USD	TV: TradingView: OTC: SMNR SA: Stock Analysis: OTC: SMNR YF: Yahoo Finance: SMNR GF: Google Finance: OTCMKTS: SMNR BA: Barron's: SMNR MS: Morningstar: PINX: SMNR

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Semnur Pharmaceuticals, Inc.

Semnur Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its lead product candidate is SP-102, a novel viscous gel formulation of corticosteroid to treat lumbosacral radicular pain, or sciatica, which is in the second Phase 3 study. The company was founded in 2013 and is headquartered in Palo Alto, California. Semnur Pharmaceuticals, Inc. operates as a subsidiary of Scilex Holding Company.

Similar Companies

Industry: Drug Manufacturers - General (United States)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 66K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 47K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 31K%	97.4	United States
Merck & Co., Inc. NYSE: MRK	$274.03B 24K%	15.1	United States
Pfizer Inc. NYSE: PFE	$149.38B 13K%	19.5	United States
Bristol-Myers Squibb Co. NYSE: BMY	$117.58B 10K%	16.8	United States

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 28K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 25K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 24K%	20.5	Switzerland
Novo Nordisk A/S CPH: NOVO-B	$181.82B 1.18T DKK 16K%	11.5	Denmark
Sanofi EPA: SAN	$110.1B 95.26B EUR 9K%	19.9	France
GSK plc LSE: GSK	$108.46B 80.96B GBP 9K%	14.6	United Kingdom

chevron_leftBack